Zydus Lifesciences Limited
ZYDUSLIFE
주식 순위
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
주가
$12.30
시가총액
$12.27B
변동 (1일)
0.06%
변동 (1년)
8.33%
국가
IN
거래 Zydus Lifesciences Limited (ZYDUSLIFE)
카테고리
Healthcare
Zydus Lifesciences Limited (ZYDUSLIFE)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 3.84
Zydus Lifesciences Limited의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 3.84입니다. 2024년 말 기준 P/B 비율은 5.10였습니다.
Zydus Lifesciences Limited의 P/B 비율 기록 (2004 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.84 | 4.02% |
| 2025 | 3.69 | -27.74% |
| 2024 | 5.10 | 79.01% |
| 2023 | 2.85 | 35.81% |
| 2022 | 2.10 | -39.59% |
| 2021 | 3.47 | 31.75% |
| 2020 | 2.64 | -22.29% |
| 2019 | 3.39 | -24.73% |
| 2018 | 4.51 | -30.66% |
| 2017 | 6.50 | 7.25% |
| 2016 | 6.06 | -27.73% |
| 2015 | 8.39 | 37.46% |
| 2014 | 6.10 | 19.12% |
| 2013 | 5.12 | -15.11% |
| 2012 | 6.03 | -18.98% |
| 2011 | 7.45 | 7.23% |
| 2010 | 6.95 | 131.38% |
| 2009 | 3.00 | 7.99% |
| 2008 | 2.78 | -38.66% |
| 2007 | 4.53 | -59.76% |
| 2006 | 11.26 | 23.48% |
| 2005 | 9.12 | -53.76% |
| 2004 | 19.72 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 31.33% |
IN
|
